NEXThaler®: A Modern and Effective Dry Powder Inhaler

Intuitive Design for Optimal Asthma Control

Despite the availability of various pharmacological interventions for asthma treatment, many patients struggle to manage their condition effectively. This often leads to increased mortality rates. Extensive research has shown that optimal device characteristics and patient preference for a device can significantly contribute to better asthma control.

Chiesi Farmaceutici S.p.a., the designer behind NEXThaler®, recognized the need for a modern inhalation product that would offer a robust technology platform for future drug product developments. The project started in 2001, aiming to develop a device that combines ease of use with effective therapeutic results.

NEXThaler® stands out from other dry powder inhalers due to its unique properties and strengths. The device contains up to 120 doses of medication and incorporates an innovative full dose feedback system. This system includes a breath-actuated mechanism that ensures a click is heard and the dose counter decrements only after effective full dose delivery. Additionally, NEXThaler® acts as a protective container closure system, reducing moisture absorption by the drug substance.

The realization of NEXThaler® involves the use of polymeric and metal materials. The device consists of two functional groups of components: the dosing group and the counting group. The dosing group meters the drug volumetrically from a bulk reservoir and delivers it to the patient. The counting group includes the breath-actuated mechanism and a dose counter that decrements with each activation.

One of the key advantages of NEXThaler® is its simplicity of use. The operating sequence requires only three steps: open, inhale, and close. The device also features a breath-actuated digital dose counter, displaying the number of doses remaining. This simplicity reduces training time and maximizes patient compliance. Furthermore, only the actuations taken are inhaled and displayed on the dose counter, reducing wastage and providing an accurate indication of the number of doses inhaled.

A recent study comparing NEXThaler® to other leading dry powder inhalers demonstrated its effectiveness, efficiency, and preference among patients. The study involved 66 participants and found that patients using NEXThaler® had significantly more successful uses and fewer task step failures compared to other devices on the market.

NEXThaler® received the Bronze A' Design Award in 2013, recognizing its outstanding and creatively ingenious design. This award highlights the device's contribution to improving the quality of life for asthma patients and its incorporation of best practices in art, science, design, and technology.

In conclusion, NEXThaler® is a modern and effective dry powder inhaler that offers a simple and accurate drug delivery system for asthma patients. With its intuitive design, innovative features, and proven effectiveness, NEXThaler® sets a new standard for dry powder inhalers on the market.